Nkarta promotes David R. Shook, M.D., to Chief Medical Officer

Nkarta, Inc.

Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.
He has extensive cell therapy development experience, including first-in-human trials with CD19 CAR-NK cells.
Dr. Shook co-developed the membrane-bound IL-15 component of Nkarta’s NK cell platform.
He continues as a practicing pediatric oncologist and transplant physician.
Prior Nkarta, he was at St. Jude Children’s Research Hospital in the lab of scientific founder Dario Campana.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.